Results 121 to 130 of about 2,643,192 (369)

Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients

open access: yesVascular Health and Risk Management, 2010
Maurizio Destro1, Nora Crikelair2, Joseph Yen2, Robert Glazer 1Azienda Ospedaliera della Provincia di Pavia, Stradella (PV), Italy; 2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USAObjective: This post hoc analysis evaluated ...
Maurizio Destro   +3 more
doaj  

Optimal Therapy of Hepatitis C Dynamics and Sampling Based Analysis [PDF]

open access: yesarXiv, 2011
We examine two models for hepatitis C viral (HCV) dynamics, one for monotherapy with interferon (IFN) and the other for combination therapy with IFN and ribavirin. Optimal therapy for both the models is determined using the steepest gradient method, by defining an objective functional which minimizes the infected hepatocyte levels, virion population ...
arxiv  

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

open access: yes, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
]   +15 more
core   +5 more sources

Addressing persistent challenges in digital image analysis of cancer tissue: resources developed from a hackathon

open access: yesMolecular Oncology, EarlyView.
Large multidimensional digital images of cancer tissue are becoming prolific, but many challenges exist to automatically extract relevant information from them using computational tools. We describe publicly available resources that have been developed jointly by expert and non‐expert computational biologists working together during a virtual hackathon
Sandhya Prabhakaran   +16 more
wiley   +1 more source

Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues

open access: yesNeuropsychiatric Disease and Treatment, 2009
William V Bobo, Richard C SheltonDepartment of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USAAbstract: Treatment-resistant depression (TRD) is a common occurrence in clinical practice.
William V Bobo   +1 more
doaj  

Exploiting evolution to treat drug resistance: Combination therapy and the double bind [PDF]

open access: yes, 2011
Although many anti cancer therapies are successful in killing a large percentage of tumour cells when initially administered, the evolutionary dynamics underpinning tumour progression mean that often resistance is an inevitable outcome, allowing for new ...
Alexander R. A. Anderson   +2 more
core   +2 more sources

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu   +7 more
wiley   +1 more source

Advances in antitumour therapy with oncolytic herpes simplex virus combinations

open access: yesDiscover Oncology
Oncolytic Virus (OVs) is an emerging approach to tumour immunity that allows the use of natural or genetically modified viruses to specifically infect and lyse tumour cells without damaging normal cells.
Xuejiao Qi
doaj   +1 more source

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

open access: yesMolecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy